Objectives To evaluate the clinical effectiveness and safety of combined induction therapy of interferon (IFN) with chemotherapy for survival of the patients with advanced non-small cell lung cancer (NSCLC) by meta-analysis.
Methods All clinical trials of addition of IFN plus chemotherapy versus chemotherapy alone for induction therapy to advanced NSCLC patients in MEDLINE (1966-2006), EMBASE (1984-2006.1) and The Cochrane Library (Issue 1,2006) were identified. The references of related studies and Education Books of ASCO and ESMO meeting were handsearched. The quality of included trials was evaluated. Data were extracted by two reviewers independently with a designed extraction form. RevMan 4.2.7 software was used for data analysis.
Results Five randomized controlled trials involving 360 patients were included. The pooled result of 3 studies showed that IFN plus chemotherapy induction treatment did not improve 1-year survival rate with RR 0.76, 95%CI 0.46 to 1.26. The pooled result of 5 studies showed that IFN plus chemotherapy induction treatment did not improve response rate with RR 1.40, (0.83 2.34). The pooled result showed that IFN plus chemotherapy induction treatment might significantly increase leukopenia and thrombocytopenia with RR 2.61,95%CI1.70 to 3.99) and RR 4.78,95%CI 1.87 to 12.19 respectively .
Conclusion Insufficient data exists to state whether IFN plus chemotherapy induction treatment can improve 1-year survival rate and response rate. IFN plus chemotherapy may increase occurrence of leucopenia and thrombocytopenia. Further studies are warranted.
Citation：
JIN Bo,LIU Yunpeng,SHI Jing,LIU Jing,ZHANG Jing,SHI Jingpu. Meta-analysis of Induction Chemotherapy Combined with Interferon in Advanced Non-small Cell Lung Cancer. Chinese Journal of Evidence-Based Medicine, 2006, 06(5): 370-375. doi:
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
王吉耀. 主编. 循证医学与临床实践. 第1版. 北京: 科学出版社; 2002. 55~81, 86~121.
|
| 2. |
Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2002; 346(1): 92-98.
|
| 3. |
Wang JY. Chief Editor. Evidence-Based Medicine and Clinical Practice. 1st edition.Beijing: Science Press; 2002. 55-81, 86-121.
|
| 4. |
Schiller JH, Storer B, Dreicer R, et al. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst, 1989; 81(22): 1739-1743.
|
| 5. |
Ardizzoni A, Salvati F, Rosso R, et al. FONICAP Trial Report. The Italian Lung Cancer Task Force. Cancer, 1993; 72(10): 2929-2935.
|
| 6. |
Halme M, Maasilta PK, Pyrhonen SO, et al. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study. Eur J Cancer, 1994; 30A(1): 11-15.
|
| 7. |
Castello G, Lerza R, Mencoboni M, et al. Cisplatin, 5-fluorouracil and alpha interferon in non small cell lung carcinoma: a toxicity study. Anticancer Res, 1994; 14(2B): 621-625.
|
| 8. |
Ardizzoni A, Addamo GF, Baldini E, et al. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. Br J Cancer, 1995; 71(1): 115-119.
|
| 9. |
Bowman A, Fergusson RJ, Allan SG, et al. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol, 1990; 1(5): 351-353.
|
- 1. 王吉耀. 主编. 循证医学与临床实践. 第1版. 北京: 科学出版社; 2002. 55~81, 86~121.
- 2. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2002; 346(1): 92-98.
- 3. Wang JY. Chief Editor. Evidence-Based Medicine and Clinical Practice. 1st edition.Beijing: Science Press; 2002. 55-81, 86-121.
- 4. Schiller JH, Storer B, Dreicer R, et al. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst, 1989; 81(22): 1739-1743.
- 5. Ardizzoni A, Salvati F, Rosso R, et al. FONICAP Trial Report. The Italian Lung Cancer Task Force. Cancer, 1993; 72(10): 2929-2935.
- 6. Halme M, Maasilta PK, Pyrhonen SO, et al. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study. Eur J Cancer, 1994; 30A(1): 11-15.
- 7. Castello G, Lerza R, Mencoboni M, et al. Cisplatin, 5-fluorouracil and alpha interferon in non small cell lung carcinoma: a toxicity study. Anticancer Res, 1994; 14(2B): 621-625.
- 8. Ardizzoni A, Addamo GF, Baldini E, et al. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. Br J Cancer, 1995; 71(1): 115-119.
- 9. Bowman A, Fergusson RJ, Allan SG, et al. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol, 1990; 1(5): 351-353.
